XXXX as a reported symptom of andropause.

@entity1 @entity172 @entity227 @entity251 @entity323 @entity6 @entity63 @entity303 @entity2414 @entity3800
Andropause seem to be less defined than menopause. This study on older @entity1 describes how they perceive and understand this aging process. A noninterventional, cross-sectional study was performed to determine what @entity1 report as symptoms of andropause to ascertain if @entity2414 was a predominant feature. The hypothesis was that @entity3800 such as @entity251 are responsible for @entity227 . As such the aging process of andropause, which is associated with declines in @entity251 levels, would lead to @entity2414 . A standardized questionnaire of 22 questions was administered to 302 outpatients of a medical center. Information on @entity1 demographics, understanding of andropause, and risk factors was collected. Of the 302 @entity1 , 71% were above 60 years and whites predominated at 87%. @entity2414 was reported in 36% of the @entity1 who felt that they had experienced andropause. It was the third most common symptom after @entity323 (46%) and general weakness (41%). Twenty-two percent of the 302 @entity1 had a history of @entity6 . Among those who reported that they had undergone andropause, @entity6 @entity1 were more likely to report @entity2414 (p = .03, OR = 1.9. CI = 1.1-3.4). Sixty-four percent of @entity1 reported the onset of andropause to be between 50 and 70 years (the median age being 50-60 years). This study highlights the importance of @entity251 in maintaining cognitive functions. It supports studies of @entity251 replacement in @entity1 undergoing andropause and who have concomitant @entity303 . The results parallel recent reports of the neuroprotective effects of @entity172 in preventing @entity303 . @entity6 is associated with @entity2414 because of the additional insults to cognitive function of the brain secondary to @entity63 .
